Omega-3 Fatty Acids Cut Mortality Risk 24% in Depressed Adults

Depression affects over 280 million people globally and is associated with elevated chronic inflammation, increased cardiovascular risk, and higher mortality. Despite omega-3 polyunsaturated fatty acids (PUFAs) being well-known for their anti-inflammatory properties, no large prospective study had specifically examined whether higher omega-3 dietary intake translates into survival benefits in depressed populations, or through what mechanisms. This study addresses that gap using nearly two decades of nationally representative U.S. data.

Researchers analyzed 6,782 depressed adults (aged ≥20) from ten NHANES cycles spanning 1999 to 2018. Depression was defined using validated tools: the WHO Composite International Diagnostic Interview (CIDI) for 1999–2004 cycles, and the Patient Health Questionnaire-9 (PHQ-9, score ≥10) for 2005–2014 cycles, plus documented antidepressant use. Omega-3 PUFA intake — total, EPA, DPA, and DHA — was assessed via 24-hour dietary recalls. Mortality data were linked through December 2019 via National Death Index records. Over 679,294 person-years of follow-up, 1,281 deaths occurred.

Cox proportional hazard models revealed that compared to the lowest omega-3 quartile, individuals in the highest quartile had a hazard ratio (HR) of 0.76 (95% CI: 0.62–0.94) for all-cause mortality — a 24% risk reduction. For cardiovascular mortality, the highest quartile showed an HR of 0.72 (95% CI: 0.50–1.02), and for other-cause mortality, HR was 0.77 (95% CI: 0.59–1.00). Cancer mortality showed HR of 0.82 (95% CI: 0.50–1.35), which did not reach statistical significance. Dose-response analyses suggested a nonlinear pattern for some cause-specific outcomes.

Quantile-based g-computation modeling disaggregated the contributions of individual omega-3 fatty acids. DPA carried the greatest weight for total mortality reduction (58.40% of the omega-3 mixture effect, p=0.002) and other-cause mortality (59.80%, p=0.011). EPA contributed most prominently to cardiovascular mortality reduction (60.4%, p=0.046). DHA, while important for brain membrane integrity, showed comparatively smaller independent contributions in this mortality context. These findings highlight that DPA — often the least studied of the three marine omega-3s — may deserve far greater clinical attention.

To probe the biological mechanisms, the team conducted causal mediation analyses using two composite biomarkers: the GNRI (integrating serum albumin and body weight to reflect nutritional-immune status) and the SII (integrating neutrophil, lymphocyte, and platelet counts to reflect systemic inflammatory burden). GNRI accounted for 8.1% of the total omega-3 PUFA–mortality association, rising to 10.5% specifically for DPA. SII mediated 6.9% of the DPA-specific mortality benefit. While these mediated proportions are modest, they provide the first direct quantitative evidence that immune-nutritional pathways partly explain how omega-3s improve survival in depressed individuals. The remaining unexplained association likely involves direct neuromodulatory effects, neurotransmitter signaling, HPA axis regulation, and mechanisms not captured by these biomarkers.

The study's population-level design, long follow-up, and rigorous adjustment for covariates (including age, sex, race, smoking, alcohol, physical activity, BMI, comorbidities, and antidepressant use) strengthen its conclusions. However, single 24-hour dietary recall data introduce measurement error, causality cannot be confirmed from observational design, and the relatively small mediated fractions suggest much of the protective mechanism remains to be characterized. Still, the findings offer a compelling case for omega-3-rich diets — particularly marine sources rich in EPA and DPA — as an adjunct strategy to reduce excess mortality in the large and vulnerable population living with depression.